Morphosys: Setzen auf marktreife Partnerprojekte und dicke Meilensteine (Seite 2081)

[Caldo]

Antwort auf Beitrag Nr.: 60.697.025 von riverstar_de am 30.05.19 10:40:49

Danke für den Link

Oberflächlich betrachtet, liest sich das ganz gut. Bei genauerer Betrachtung bin ich allerdings der Meinung, dass man das etwas relativieren muss.

Die Daten sind gut genug, um weiterzumachen, ob es allerdings auch für eine Phase 3 (Erwachsene) reicht, werden dann doch erst die 12-Monatsdaten zeigen.

Davon unabhängig wird es aber ziemlich sicher eine Phase-3-Zulassungsstudie bei Kindern und Jugendlichen in Europa geben.

[Zurcher]

Selbst am Feiertag setzt sich der Absturz fort. Insider?

[riverstar_de]

POSITIVE EARLY 6 MONTH DATA FROM THE OPEN LABEL ARM OF THE PHASE 2B CLINICAL STUDY IN ADULT PATIENTS WITH TYPE I, III OR IV OSTEOGENESIS IMPERFECTA TREATED WITH THE ANTI-SCLEROSTIN ANTIBODY, BPS-804 (SETRUSUMAB)

https://www.mereobiopharma.com/news-and-events/press-release…

[milchbubi]

Antwort auf Beitrag Nr.: 60.693.809 von Zurcher am 29.05.19 20:13:26

Mein Süßer, ich muss dich heute Abend mal briefen. Wieso hast Du heute nicht den Markt beobachtet?

[Zurcher]

Antwort auf Beitrag Nr.: 60.692.594 von Caldo am 29.05.19 18:14:11

Zitat von Caldo: Mühsam klettert der Kurs nach oben, um dann wieder abzustürzen - aber das muss man bei Biotech-Aktien aushalten, geht ja auch nicht nur MOR so.

In der Zwischenzeit - bis zum nächsten Anstieg - wieder News sammeln, um sich zu vergewissern, dass man bei dem Invest die richtige Entscheidung getroffen hat. Das hilft zwar dem Kurs nicht, gibt aber vielleicht ein besseres Gefühl

MOR ignoriert seit längerem jegliche positiven News, genauer gesagt seit der Datierung der Moroney-Personalie.

Stattdessen immer wieder solche nachrichtenlosen Abstürze wie heute, gepaar mit einer stetig ansteigenden Short-Quote.

Ich verweise einmal mehr an die Paralelle Intershop Ende 2000. Hier droht bitterböses!
By the way, einem Uwe Hück hätte man auch nie böses zugetraut. Im Februar hat er dann Knall auf Fall Porsche verlassen. Gestern leitete die Staatsanwaltschaft Untersuchungen vor Ort ein....

[Caldo]

PRV-300

Das Projekt ist in UC wohl gescheitert. Vielleicht geht es in anderen Indikationen weiter.


Provention Bio Announces Top-Line Results from its Phase 1b PULSE Clinical Trial of PRV-300 in Patients with Moderate-to-Severe Ulcerative Colitis

PRV-300 met the primary safety and tolerability endpoint over the twelve-week study period and also demonstrated TLR3 target engagement and proof-of-mechanism. However, improvements in secondary and exploratory clinical, endoscopic, histologic and other UC-related efficacy endpoints were not observed over background medication, suggesting that elevated TLR3 gene signatures previously observed in UC patients, as well as in PULSE, are downstream or circumstantial effects that do not contribute significantly to causal pathology.

PRV-300 did not demonstrate an upstream effect on clinically relevant parameters in UC, but its favorable safety and tolerability profile, and demonstration of proof-of-mechanism, may offer an opportunity to sub-license this asset for evaluation in other indications, including severe influenza and emerging viral diseases, where an anti-TLR3 antibody has been successful in preventing the release of toxic inflammatory mediators in animal models."

http://investors.proventionbio.com/2019-05-08-Provention-Bio…

[Caldo]

Auch bei Ianalumab scheinen sich weitere Möglichkeiten zu ergeben

Combination therapy for treating advanced drug-resistant acute lymphoblastic leukemia

... Our results highlight the potential of using a combination of VAY736 antibody with EW-7197 to treat advance-stage, drug-resistant B-ALL patients.

http://cancerimmunolres.aacrjournals.org/content/early/2019/…

[Caldo]

Auch zu Guselkumab mehrere Abstracts

eular
European Congress of Rheumatology 2019
Madrid, 12.-15. June


ASSESSMENT OF DISEASE ACTIVITY USING RAPID3 AND EVALUATION OF TREATMENT EFFECT OF Guselkumab IN PATIENTS WITH PSA: RESULTS FROM A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 CLINICAL TRIAL

Conclusion: GUS-treated PsA patients demonstrated significant improvement in RAPID3 compared to PBO. RAPID3 is simple and feasible to use in routine clinical care, and it correlates well with other comprehensive PsA-specific disease activity measures.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…" target="_blank" rel="nofollow ugc noopener">http://scientific.sparx-ip.net/archiveeular/index.cfm?search…



COMPARING COMPOSITE MEASURES OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED PHASE 2 TRIAL WITH Guselkumab

Conclusion: Regardless of the PsA-specific composite index employed, GUS significantly improved disease activity and achieved clinically meaningful therapeutic targets such as low/minimal disease activity or remission. PASDAS and GRACE indices were more sensitive than mCPDAI and DAPSA in detecting changes in disease activity by Guselkumab treatment.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…" target="_blank" rel="nofollow ugc noopener">http://scientific.sparx-ip.net/archiveeular/index.cfm?search…



CONSISTENT EFFICACY IN PATIENT SUBGROUPS ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS: RESULTS FROM A PHASE 2 STUDY OF Guselkumab IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Conclusion: In this phase 2 trial of patients with PsA, GUS demonstrated efficacy consistently across subgroups of pts according to baseline demographics, disease characteristics, and PsA-medication use. The relationship between baseline characteristics and clinical outcome will be further explored in phase 3 studies with a larger PsA population.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…


EFFICACY OF Guselkumab IN PSORIASIS PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS WITH INVOLVEMENT OF THE SCALP, NAILS, HANDS, AND FEET: A POOLED ANALYSIS FROM 2 PIVOTAL PHASE 3 PSORIASIS STUDIES

Conclusion: GUS-treated PsO pts with self-reported PsA showed clinically meaningful improvements vs aDA in ss-IGA & hf-PGA scores at wks16 & 24. Although improvements in f-PGA & NAPSI were similar in pts treated with GUS vs. ADA at earlier timepoints, numerically greater differences were observed with GUS by wk48, likely requiring the additional duration to discriminate between treatments in this slow-growing cutaneous appendage.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…


Guselkumab WAS MORE EFFECTIVE THAN SECUKINUMAB IN PATIENTS WITH PLAQUE PSORIASIS AND THE SUBSET OF PATIENTS WITH SELF-REPORTED PSORIATIC ARTHRITIS IN THE RANDOMIZED, DOUBLE-BLIND, HEAD-TO-HEAD COMPARISON STUDY ECLIPSE OVER 1 YEAR

Conclusion: In the subset of patients with self-reported PsA in the ECLIPSE study, GUS demonstrated better maintenance of response and higher efficacy at approximately one year compared with SEC in the treatment of moderate to severe plaque PsO. These findings were consistent with those for the overall study population of patients with plaque PsO. AEs observed were generally consistent with the established safety profiles for GUS and SEC.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…


THE EFFECT OF Guselkumab ON PASDAS, GRACE INDEX, MCPDAI, AND DAPSA: RESULTS FROM A PHASE 2 STUDY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS

Conclusion: GUS demonstrated consistent improvements based on all PsA composite indices evaluated, and efficacy was maintained through Week44.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…


USTEKINUMAB AND Guselkumab TREATMENT RESULTS IN DIFFERENCES IN SERUM IL17A, IL17F AND CRP LEVELS IN PSORIATIC ARTHRITIS PATIENTS: A COMPARISON FROM USTEKINUMAB PH3 AND Guselkumab PH2 PROGRAMS

Conclusion: These results underscore the relevance of the IL23/Th17 pathway in PsA, with GUS treatment providing a stronger suppression of the pathway than UST treatment. The significant associations of changes in IL17A and IL17F levels with GUS treatment with PASI75 and ACR20 response, respectively, support the importance of the IL23/Th17 pathway for both skin and joint pathologies. The associations of reduction in CRP levels with both UST and GUS treatment also reinforce the role of acute phase inflammation in joint pathology.

http://scientific.sparx-ip.net/archiveeular/index.cfm?search…

[Caldo]

Otilimab

eular
European Congress of Rheumatology 2019
Madrid, 12.-15. June

Abstracts

GSK3196165 AN INVESTIGATIONAL ANTI-GM-CSF MONOCLONAL ANTIBODY, IMPROVES PATIENT REPORTED OUTCOMES IN A PHASE IIB STUDY OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

Conclusion: The results of this Phase IIb study showed that GSK3196165 substantially improved the scores of a range of PRO measures among RA patients. In particular, there was a highly significant improvement in pain; a key symptom of RA. These effects were observed despite achieving much lower drug exposure than predicted. Further studies are required to confirm the additional patient relevant benefits that are expected to arise from increased exposure to GSK3196165.

http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=a…

[Caldo]

Mühsam klettert der Kurs nach oben, um dann wieder abzustürzen - aber das muss man bei Biotech-Aktien aushalten, geht ja auch nicht nur MOR so.

In der Zwischenzeit - bis zum nächsten Anstieg - wieder News sammeln, um sich zu vergewissern, dass man bei dem Invest die richtige Entscheidung getroffen hat. Das hilft zwar dem Kurs nicht, gibt aber vielleicht ein besseres Gefühl

Der Beitrag von Kmastra zeigt schön die Möglichkeiten von Tafasitamab, aber bis es soweit ist, dauert es halt noch.

Auch zu Tremfya gab es heute Neuigkeiten:

Janssen Announces Health Canada Approval of TREMFYA ONE-PRESS™ (guselkumab) - A Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

https://www.newswire.ca/news-releases/janssen-announces-heal…